Answers are grounded in this paper and cite their sources.
targeted therapies and discuss evolving therapeutic strategies designed to overcome adaptive resistance in KRAS mutant malignancies.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: